H. pylori  is classified by the WHO  as a Group I biological carcinogen and is a major risk factor for chronic gastritis, peptic ulcers, and even gastric cancer. Given the relatively high infection rate in many regions, early screening and precise diagnosis are critical for the prevention and management of gastric diseases. As a professional medical diagnostics company, we offer a comprehensive one-stop testing portfolio—from initial screening to precise quantification—to meet diverse clinical and screening needs.

Efficient Screening: C13 and C14 Urea breath  analyzer and test kit

For large-scale health checkups and outpatient screening, the C13/C14 Urea Breath Test is internationally recognized as the gold standard for H. pylori detection, offering non-invasive testing with accuracy exceeding 95%. The C13 isotope is non-radioactive and suitable for all populations, including pregnant women and children, while the C14 test provides a cost-effective and efficient alternative.

In parallel, we offer convenient HP-AB (antibody) and HP-AG (antigen) rapid test kits. The HP-AB test detects antibodies using fingertip blood or serum, delivering results within 15 minutes—ideal for epidemiological surveys. The HP-AG test detects antigens in stool samples, directly reflecting active infection status. It serves as an effective adjunct to the breath test, particularly useful for special populations where alternative testing may be challenging.

Precision Quantification: Fluorescence Immunoassay Technology

To meet the clinical demand for disease monitoring and therapeutic efficacy assessment, we have introduced quantitative HP-AG and HP-AB reagents powered by the WIZ-101 and WIZ-A203 platforms. This system employs time-resolved fluorescence immunochromatography, combining specific antibodies with fluorescent microspheres. Unlike traditional qualitative test strips, this technology enables precise quantitative measurement of antibody/antigen concentrations. This not only assists physicians in assessing infection severity but also enables accurate evaluation of eradication therapy outcomes, providing more reliable data for clinical decision-making.

From mass spectrometry-based breath testing to immunochromatography, and from qualitative screening to fluorescence-based quantification, we are committed to delivering a comprehensive product portfolio that empowers healthcare institutions to achieve precise prevention and control of gastric H. pylori infections.